Follicum AB (“Follicum”) announces that the company has today received a preliminary approval from the European Patent Office (EPO) of a patent application concerning the company’s new class of peptides that are being developed to treat diabetes.
Follicum’s patent application with publication number EP 3 618 845 comprises new peptides and their use in the treatment of diabetes. EPO has issued an “Intention to Grant”, which means that the Patent Office intends to grant the company’s patent application. The forthcoming patent will be valid until May 4, 2038.
CEO Jan Alenfall comments:
“The notification about the upcoming EPO approval is very gratifying and demonstrates the uniqueness and strength of our diabetes project. Patent approval in Europe is very important for the patent portfolio and increases the value of our diabetes project.”
Diabetes is rapidly increasing globally. The disease is characterized by poor blood sugar control due to defective insulin signalling, which causes serious sequelae such as cardiovascular disease, renal failure, obesity, blindness and diabetic foot ulcers. Diabetes as well as its accompanying illnesses represent a major burden, partly for the individual patient, but also for the entire health care system. There is thus an already large and growing global need for new therapies that address effective control of glucose levels in combination with preventive effects on the various diabetic complications.
For further information, please contact:
Jan Alenfall – CEO, Follicum AB
Telephone: +46 46 19 21 97
This information is information that Follicum is obliged to make public according to the EU Market Abuse Regulation. The information was provided through the agency of the contact persons above, for publication on the 20th of March, 2020.
About Follicum AB
Follicum is a biotech company focused on the discovery and development of peptide-based drugs. The primary focus is in hair growth stimulation, where Follicum has obtained very promising results with FOL-005 in a recently completed clinical trial. In diabetes, Follicums research has resulted in a new peptide class which significantly increases the release of insulin in pre-clinical models. The company was founded in 2011, and is based in Lund, Sweden. Follicum is listed on the Swedish small cap exchange Spotlight since 2014. www.follicum.com.